Cano C, Torres R, Pérez G, Hernández M, Aguíñiga MA, Peredo G, Macías O, Granados E, Anda J, Ochoa RJ, Arreola MA

Language: Spanish
References: 14
Page: 1-6
PDF size: 163.59 Kb.

ABSTRACT

Background: Long-term efficacy of antiretroviral treatment is one of the main objectives. Saquinavir with two nucleoside analogue reverse transcriptase inhibitors is an efficient schemes during five years of treatment.
Objective: To prove the long-term virological and immunological efficacy of antiretroviral scheme with saquinavir in a retrospective study.
Material and methods: Eighty-three files of adult patients with HIV/AIDS infection were reviewed. These patients were given an antiretroviral scheme with saquinavir and maintained the same regimen during more than five years, in eight Mexican specialized clinics. Data of the clinical files about efficacy and safety of the saquinavir schemes reinforced with low doses of ritonavir were obtained.
Results: Eighty-three patients were included (68 males), who maintained the treatment scheme based on soft-gel capsules of saquinavir from 1999 to 2006. Average basal viral load was of 121,546 RNA-HIV copies. Basal lymphocytes CD4+ average was of 227 cells/mL. After one year of treatment more than 80% of patients achieved and maintained undetectable viral load. Increased average of CD4+ lymphocytes was higher than 96 cells/mL after one year and higher than 500 cells/mL by fifth year. The informed adverse side effects on gastrointestinal tract are unspecific and transitory. No patients with severe or significant dyslipidemia or deaths were informed.
Conclusion: In Mexico it is very important to inform the experiences with the antiretroviral treatment in order to improve decisions with local data in patients with HIV/AIDS. Saquinavir is an attractive treatment option due to its long-term efficacy (more than five years). The availability of its formula in tablets of 500 mg will improve the compliance and, thus, durability of antiretroviral schemes including it.

REFERENCES

1. Bartlett JG, Gallant JE. Medical management of HIV infection. 2003 ed. Baltimore: Johns Hpkins University, 2003;p:376.

2. Carpenter CCJ, Cooper DA, Fischl MA, et al. Antiretroviral therapy in adults; updated recommendations of the International AIDS Society-USA Panel. JAMA 2004;383:581-90.

3. CDC 1993 revised classification system for HIV. Infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992;41(RR-17):1-19.

4. DeJesus E, Grinsztejn B, Rodríguez C, Nieto L, et al. Efficacy and safety of atazanavir with ritonavir or saquinavir vs lopinavir/ ritonavir in patients who have experienced virologic failure on multiple HAART regimens: 48 weeks results from BMS A1424-045. 11th Conference of retrovirus and opportunistc infections, February 8-11, 2004; San Francisco, California. Abstract 547.

5. EACS (European AIDS Clinical Society). European Treatment Guidelines. Disponibles en: www.eacs.ws/guide/index.htm.

6. Katlama C, Arastéh J, Clotet B, et al. Enfuvirtide TORO Studies: 48 weeks results confirm 24 weeks findings. II IAS Conference on HIV Pathogenesis and Treatment. Paris, France, July 2003 (Abstract LB2).

7. Kirk O, Pedersen, Law M, et al. Analysis of virological efficacy in trials of antiretroviral regimens. Drawbacks of not including viral load measurements after premature discontinuation of therapy. Antivir Ther 2002;7: 271-81.

8. Manheimer S, Fiedland G, Matts J. The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clin Infect Dis 2002;34:1115-21.

9. Paredes R, Clotet B. New antiretroviral drugs and approaches to HIV treatment. AIDS 2003;17(18s):S85-S96.

10. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000;133:21-30.

11. Slim, M, Avihingsanon, A, Ruxrungtham K, Schutz M, et al. Saquinavir/r bid vs Lopinavir/r bid plus Emtricitabine/Tenofovir qd in ARV-naive HIV-1-Infected Patients: Gemini Study. 8th International Congress on Drug Therapy in HIV Infection, Glasgow, UK, 12-16 November 2006, Oral and Poster PL2.5

12. Wood E, Hogg RS, Yip B, Harrigan PR, et al. Effect of medication adherence on survival of HIV-infected adults who start HAART when the CD4+ cell count is 200 to 350 cell/ml. Ann Intern Med 2003;139:810-6.

13. World Health Organization. Scaling up antiretroviral therapy in resource limited settings. Treatment guidelines for a public health approach, December 2003. In: http://www.who. int/3by5/publications/documents/arv_guidelines/

14. Tarwater PM, Parish M, Gallant JE. Prolonged treatment interruption after immunologic response to highly active antiretroviral therapy. Clin Infect Dis 2003;37:1541-8.